THE WOODLANDS, Texas, Aug. 30, 2011 /PRNewswire/ — Lexicon Pharmaceuticals, Inc.
(Nasdaq:
LXRX), a biopharmaceutical company focused on discovering
breakthrough treatments for human disease, announced today that Arthur T.
Sands, M.D., Ph.D., Lexicon’s president and chief executive
officer, will present at the Stifel Nicolaus Healthcare Conference
in Boston on Wednesday, September 7, 2011 at 2:40 p.m. Eastern
Time. Dr. Sands will provide an overview on Lexicon’s
clinical development programs and milestones.
A live webcast of the event may be accessed on Lexicon’s
corporate website at www.lexpharma.com. An
archived version of the webcast will be available for 30 days after
the event on the company’s website.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
breakthrough treatments for human disease. Lexicon currently
has four drug programs in mid-stage development for diabetes,
irritable bowel syndrome, carcinoid syndrome and rheumatoid
arthritis, all of which were discovered by Lexicon’s research team.
Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has
focused drug discovery efforts on these biologically-validated
targets to create its extensive pipeline of clinical and
preclinical programs. For additional information about
Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking” statements,
including statements relating to Lexicon’s growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as w
‘/>”/>
SOURCE
